IPHA Stock Summary and Trading Ideas (Innate Pharma S.A. - American Depositary Shares | NASDAQ:IPHA)

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol IPHA.

As of April 24, 2024, IPHA stock price climbed to $2.46 with 672 million shares trading.

IPHA has a market cap of $198.87 million. This is considered a Micro Cap stock.

In the last 3 years, IPHA stock traded as high as $11.95 and as low as $1.81.

The top ETF exchange traded funds that IPHA belongs to (by Net Assets): CNCR, APIE, DFSI.

IPHA has underperformed the market in the last year with a price return of -17.7% while the SPY ETF gained +24.2%. IPHA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.1% and -5.4%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

IPHA support price is $2.21 and resistance is $2.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IPHA stock will trade within this expected range on the day.